Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 6/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.44 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.44 |
| ▸ | GPR6 | P46095 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253109 | 0.97 | CCR6 (0.48) | CCR6TBXA2RSFRP1GPR6THRB | |
| SCHEMBL2378606 | 0.93 | CCR6 (0.52) | CCR6TBXA2RSFRP1GPR6L3MBTL1 | |
| SCHEMBL12317714 | 0.87 | TBXA2R (0.46) | TBXA2RSFRP1THRBKMT2A | |
| SCHEMBL12253116 | 0.87 | TBXA2R (0.44) | TBXA2RTHRBL3MBTL1KMT2A | |
| SCHEMBL12253113 | 0.86 | SFRP1 (0.47) | CCR6TBXA2RSFRP1GPR6KMT2A | |
| SCHEMBL694148 | 0.86 | ALDH1A1 (0.49) | CCR6TBXA2RGPR6L3MBTL1ALDH1A1 | |
| SCHEMBL2378683 | 0.86 | SFRP1 (0.49) | CCR6TBXA2RSFRP1GPR6THRB | |
| SCHEMBL15197156 | 0.85 | KMT2A (0.47) | CCR6TBXA2RGPR6L3MBTL1ALDH1A1 | |
| SCHEMBL12253065 | 0.84 | ALK (0.43) | CCR6TBXA2RALDH1A1KMT2A | |
| SCHEMBL2380044 | 0.84 | PDE5A (0.44) | CCR6TBXA2RALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547655-B1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2547655-B1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741894-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2547655-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011116161-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116161-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230487-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CCR6 5/4885TBXA2R 2704/4885SFRP1 3491/4885 |
| US-20140221428-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CCR6 5/4885TBXA2R 2704/4885SFRP1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.